Prilocaine
Modify Date: 2024-01-02 17:20:48
Prilocaine structure
|
Common Name | Prilocaine | ||
|---|---|---|---|---|
| CAS Number | 721-50-6 | Molecular Weight | 220.311 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 361.6±25.0 °C at 760 mmHg | |
| Molecular Formula | C13H20N2O | Melting Point | 37-38ºC | |
| MSDS | N/A | Flash Point | 134.3±23.3 °C | |
Use of PrilocainePrilocaine is a local anesthetic of the amino amide type.Target: OthersPrilocaine is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils L?fgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a preparation for dermal anesthesia, for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA). In some patients, a metabolite of prilocaine may cause the unusual side effect of methemoglobinemia, which may be treated with methylene blue. Maximum dosage for dental use: 8.0 mg/kg (2.7 mg/lb), with a maximum dose of 500 mg.Eutectic Mixture of Local Anesthetics (EMLA) containing 5% lidocaine and prilocaine in a cream was found to give effective topical analgesia in normal and diseased skin, making it useful for superficial surgery and various other clinical procedures. To be effective, an adequate amount must be applied under occlusion and at the right time before the intervention. |
| Name | prilocaine |
|---|---|
| Synonym | More Synonyms |
| Description | Prilocaine is a local anesthetic of the amino amide type.Target: OthersPrilocaine is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils L?fgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a preparation for dermal anesthesia, for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA). In some patients, a metabolite of prilocaine may cause the unusual side effect of methemoglobinemia, which may be treated with methylene blue. Maximum dosage for dental use: 8.0 mg/kg (2.7 mg/lb), with a maximum dose of 500 mg.Eutectic Mixture of Local Anesthetics (EMLA) containing 5% lidocaine and prilocaine in a cream was found to give effective topical analgesia in normal and diseased skin, making it useful for superficial surgery and various other clinical procedures. To be effective, an adequate amount must be applied under occlusion and at the right time before the intervention. |
|---|---|
| Related Catalog | |
| References |
[2]. Juhlin L, et al. EMLA: a new topical anesthetic. Adv Dermatol. 1990;5:75-91; discussion 92. |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 361.6±25.0 °C at 760 mmHg |
| Melting Point | 37-38ºC |
| Molecular Formula | C13H20N2O |
| Molecular Weight | 220.311 |
| Flash Point | 134.3±23.3 °C |
| Exact Mass | 220.157562 |
| PSA | 41.13000 |
| LogP | 1.74 |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Index of Refraction | 1.543 |
| Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| HS Code | 2924299090 |
|---|
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
| UNII:046O35D44R |
| Astra 1515 |
| Propanamide, N-(2-methylphenyl)-2-(propylamino)- |
| Astra 1512 |
| N-(2-méthylphényl)-2-(propylamino)propanamide |
| EINECS 211-957-0 |
| prilocainum [INN_la] |
| N-(2-Methylphenyl)-N-propylalaninamide |
| Citanest |
| Pricocaine |
| N-(2-Methylphenyl)-2-(propylamino)propanamid |
| MFCD00048681 |
| N-(2-methylphenyl)-N2-propylalaninamide |
| prilocaine |
| Propitocaine |